BeiGene

Our flagship U.S. biologics manufacturing and clinical R&D facility, opened this week in Hopewell, N.J., represents a huge step forward in our continuing growth as a leading #oncology company and the expansion of our global footprint. We’re committed to making a significant investment in New Jersey to ensure we’re a responsible and positive force in the community. The $800 million investment we’ve made in the site will create more than 100 high-tech skilled jobs locally by the end of 2025. Learn more in this Fierce Pharma article: https://bit.ly/3zZC6iU

We believe in advancing impactful #oncology medicines for patients around the world. Thanks to one of the largest and most prolific oncology R&D teams in the industry, our broad and growing pipeline has the potential to address 80 percent of #cancers by incidence.      Learn more about our pipeline at https://bit.ly/3RGlwdO. 

Swipe through to see highlights from the grand opening of our flagship U.S. facility in Hopewell, N.J. earlier today. This state-of-the-art manufacturing and clinical R&D site will help us advance innovative medicines more quickly to meet the needs of more #cancer patients around the world. Learn more at https://bit.ly/463Zmbh. Courtney Peters-Manning Township of Hopewell, Mercer County, New Jersey Amy Sutton Crossroads4Hope, A Network of Cancer Support John Oyler Michael Schoen

Today we’re opening our flagship U.S. facility in Hopewell, N.J. to help advance current and future innovative medicines to meet the needs of more patients with #cancer. This 42-acre site houses state-of-the-art biologics manufacturing capabilities and a clinical R&D center that will continue expanding and scaling our unique capabilities around the world. https://lnkd.in/evxVxsY6

We believe in innovating with urgency to develop the medicines of tomorrow. Our efforts extend beyond generating our industry-leading #oncology pipeline; our 3,200 global clinical development team is advancing our investigational medicines with an urgency inspired by the patients we serve worldwide.     Learn more about our clinical trials at https://bit.ly/4cun16Z. 

We're pleased to welcome Aaron Rosenberg, CFA as Chief Financial Officer, effective July 22. Aaron brings a wealth of expertise and invaluable financial leadership to BeiGene as we responsibly scale our business, look to reinforce our global leadership in #hematology, and build future franchises in other highly prevalent cancers, including lung, breast and gastrointestinal. Learn more: https://bit.ly/3Wb4Ts9

Our flagship U.S. manufacturing and clinical R&D facility is opening next week in Hopewell, N.J.! This state-of-the-art facility will help us scale production of our innovative medicines and portfolio in the future to better serve patients around the world. Read this Axios article to learn more. https://bit.ly/HWRD

Our PD-1 inhibitor is now available for eligible patients in Austria, making it the first country in Europe to offer access to this innovative treatment option. We are looking forward to providing more positive impact across Europe.

The opening of our flagship U.S. manufacturing and clinical research and development facility in Hopewell, N.J. later this month is an important part of our efforts to bring our innovative #cancer medicines to more patients. Hear from our Head of Corporate Affairs, Shreya Jani, on what this state-of-the-art facility represents and learn more here: https://lnkd.in/ej7JJ3fy

We believe in leading with science to drive innovation. Our dedicated research team is delivering one of the largest and most compelling #oncology pipelines in the industry, uniting cutting-edge science with global development scale to advance tomorrow’s #cancer medicines.     Learn more about our approach to cancer biology and areas of innovation at https://bit.ly/3RE0Bs1.